The race for combined checkpoint inhibition in NSCLC

Mené sur 102 patients atteints d'un cancer avancé du poumon non à petites cellules, cet essai multicentrique de phase Ib évalue la dose maximale tolérée et l'activité antitumorale d'un traitement combinant le durvalumab, un anticorps anti PD-L1, et le trémélimumab, un anticorps anti CTLA-4

Résumé en anglais

After approval of the anti-PD-1 drugs nivolumab and pembrolizumab for treatment of non-small cell lung cancer (NSCLC), a near frenzy of attempts were made to combine inhibitors of the PD-1 immune checkpoint with other drugs. In The Lancet Oncology, Scott Antonia and colleagues report on the combination of durvalumab (anti-PD-L1 antibody) and tremelimumab (anti-CTLA-4 antibody) in patients with NSCLC. Unlike some efforts, which were based on scant evidence, this combination has a sound scientific basis: dual-checkpoint inhibition is an established treatment option for patients with advanced melanoma.